Impaired Succinate Oxidation Prevents Growth and Influences Drug Susceptibility in Mycobacterium tuberculosis

被引:14
|
作者
Adolph, Cara [1 ,2 ]
McNeil, Matthew B. [1 ,2 ]
Cook, Gregory M. [1 ,2 ]
机构
[1] Univ Otago, Sch Biomed Sci, Dept Microbiol & Immunol, Dunedin, New Zealand
[2] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
来源
MBIO | 2022年 / 13卷 / 04期
关键词
CRISPR interference; Mycobacterium tuberculosis; succinate dehydrogenase; FUMARATE REDUCTASE; TRANSCRIPTIONAL REPRESSION; QUINONE OXIDOREDUCTASES; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; DEHYDROGENASE; PERSISTENCE; EXPRESSION; PROTEIN; INDUCE;
D O I
10.1128/mbio.01672-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
New drugs are urgently required to combat the tuberculosis epidemic that claims 1.5 million lives annually. Inhibitors of mycobacterial energy metabolism have shown significant promise clinically; however, further advancing this nascent target space requires a more fundamental understanding of the respiratory enzymes and pathways used by Mycobacterium tuberculosis. Succinate is a major focal point in mycobacterial metabolism and respiration, serving as both an intermediate of the tricarboxylic acid (TCA) cycle and a direct electron donor for the respiratory chain. Mycobacterium tuberculosis encodes multiple enzymes predicted to be capable of catalyzing the oxidation of succinate to fumarate, including two different succinate dehydrogenases (Sdh1 and Sdh2) and a separate fumarate reductase (Frd) with possible bidirectional behavior. Previous attempts to investigate the essentiality of succinate oxidation in M. tuberculosis have relied on the use of single-gene deletion mutants, raising the possibility that the remaining enzymes could catalyze succinate oxidation in the absence of the other. To address this, we report on the use of mycobacterial CRISPR interference (CRISPRi) to construct single, double, and triple transcriptional knockdowns of sdhA1, sdhA2, and frdA in M. tuberculosis. We show that the simultaneous knockdown of sdhA1 and sdhA2 is required to prevent succinate oxidation and overcome the functional redundancy within these enzymes. Succinate oxidation was demonstrated to be essential for the optimal growth of M. tuberculosis, with the combined knockdown of sdhA1 and sdhA2 significantly impairing the activity of the respiratory chain and preventing growth on a range of carbon sources. Moreover, impaired succinate oxidation was shown to influence the activity of cell wall-targeting antibiotics and bioenergetic inhibitors against M. tuberculosis. Together, these data provide fundamental insights into mycobacterial physiology, energy metabolism, and antimicrobial susceptibility. IMPORTANCE New drugs are urgently required to combat the tuberculosis epidemic that claims 1.5 million lives annually. Inhibitors of mycobacterial energy metabolism have shown significant promise clinically; however, further advancing this nascent target space requires a more fundamental understanding of the respiratory enzymes and pathways used by Mycobacterium tuberculosis. Succinate is a major focal point in mycobacterial metabolism and respiration; yet, the essentiality of succinate oxidation and the consequences of inhibiting this process are poorly defined. In this study, we demonstrate that impaired succinate oxidation prevents the optimal growth of M. tuberculosis on a range of carbon sources and significantly reduces the activity of the electron transport chain. Moreover, we show that impaired succinate oxidation both positively and negatively influences the activity of a variety of antituberculosis drugs. Combined, these findings provide fundamental insights into mycobacterial physiology and drug susceptibility that will be useful in the continued development of bioenergetic inhibitors.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Rapid Diagnosis of Mycobacterium tuberculosis Infection and Drug Susceptibility Testing
    Wilson, Michael L.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (06) : 812 - 819
  • [22] Development of a microdilution method to evaluate Mycobacterium tuberculosis drug susceptibility
    Banfi, E
    Scialino, G
    Monti-Bragadin, C
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (05) : 796 - 800
  • [23] CONVENTIONAL AND RADIOMETRIC DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM-TUBERCULOSIS
    SALFINGER, M
    EXPERIENTIA, 1985, 41 (04): : 538 - 538
  • [24] Drug susceptibility test of Mycobacterium tuberculosis by nitrate reductase assay
    Ani, Agatha E.
    Dalyop, Y. B.
    Agbaji, O.
    Idoko, J.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2009, 3 (01): : 16 - 19
  • [25] RADIOMETRIC AND CONVENTIONAL DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM-TUBERCULOSIS
    HOEL, T
    ENG, J
    APMIS, 1991, 99 (11) : 977 - 980
  • [26] Rapid drug susceptibility test of mycobacterium tuberculosis by bioluminescence sensor
    Lu, B
    Xu, SQ
    Chen, ZF
    Zhou, YK
    INTERNATIONAL CONFERENCE ON SENSOR TECHNOLOGY (ISTC 2001), PROCEEDINGS, 2001, 4414 : 133 - 136
  • [27] Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay
    Coban, AY
    Birinci, A
    Ekinci, B
    Durupinar, B
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (03) : 304 - 306
  • [28] Nitrate reductase assay for drug susceptibility testing of Mycobacterium tuberculosis
    Panaiotov, S
    Kantardjiev, T
    JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) : 3881 - 3881
  • [29] RAPID DRUG-SUSCEPTIBILITY TESTING OF MYCOBACTERIUM-TUBERCULOSIS
    SNIDER, DE
    GOOD, RC
    KILBURN, JO
    LASKOWSKI, LF
    LUSK, RH
    MARR, JJ
    REGGIARDO, Z
    MIDDLEBROOK, G
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1981, 123 (04): : 402 - 406
  • [30] A simplified pyrazinamidase test for pyrazinamide drug susceptibility in Mycobacterium tuberculosis
    Aono, Akio
    Chikamatsu, Kinuyo
    Yamada, Hiroyuki
    Igarashi, Yuriko
    Murase, Yoshiro
    Takaki, Akiko
    Mitarai, Satoshi
    JOURNAL OF MICROBIOLOGICAL METHODS, 2018, 154 : 52 - 54